Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials.
| Autor: | Soung J; Southern California Dermatology, Inc, Santa Ana, CA, USA., Ständer S; University Hospital Westphalian Wilhems University, Munster, Germany., Gutermuth J; Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Jette, Belgium., Pau-Charles I; Almirall, Barcelona, Spain., Dawson Z; Eli Lilly and Company, Indianapolis, IN, USA., Yang FE; Eli Lilly and Company, Indianapolis, IN, USA., Sun L; Eli Lilly and Company, Indianapolis, IN, USA., Pierce E; Eli Lilly and Company, Indianapolis, IN, USA., Elmaraghy H; Eli Lilly and Company, Indianapolis, IN, USA., Stein-Gold L; Clinic for Dermatology, Henry Ford Health System, Detroit, MI, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of dermatological treatment [J Dermatolog Treat] 2024 Dec; Vol. 35 (1), pp. 2329240. Date of Electronic Publication: 2024 Apr 28. |
| DOI: | 10.1080/09546634.2024.2329240 |
| Abstrakt: | Background: Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo. Objectives: We assess improvements in itch and sleep interference due to itch and their impact on QoL measurements after treatment. Methods: Data were analyzed from ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) in patients with moderate-to-severe AD. QoL was evaluated using Dermatology Life Quality Index (DLQI) at Week 16 in patients (>16 years of age) who were itch responders/non-responders (defined as ≥4-point improvement in Pruritus Numeric Rating Scale) or Sleep-Loss Scale responders/non-responders (defined as ≥2-point improvement in itch interference on sleep). Results: In ADvocate1 and ADvocate2, significantly greater proportions of itch responders had a clinically meaningful improvement in measures related to QoL (DLQI scores (0/1), ≤5 DLQI total score and ≥4-point DLQI improvement) compared to itch non-responders. In both studies, a significantly greater proportion of Sleep-Loss Scale responders, reported a DLQI score of (0/1), DLQI total score of ≤5 and DLQI improvement of ≥4 points compared to Sleep-Loss Scale non-responders. Conclusions: Improvement in itch and sleep interference due to itch is associated with improvement in the QoL of patients after treatment with lebrikizumab for moderate-to-severe AD. ClinicalTrials.gov registration NCT04146363 (ADvocate1) and NCT04178967 (ADvocate2). |
| Databáze: | MEDLINE |
| Externí odkaz: |
|